79 patents
Page 2 of 4
Utility
Prodrug modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
31 May 22
The present invention relates to prodrug compounds and their use in the treatment of Cystic Fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
Didier Philippe Robert Schils, Sam Bob Corveleyn, Herman Augustinus De Kock, Matthew Beau Dufek
Filed: 2 Jun 20
Utility
Compounds and pharmaceutical compositions thereof for the treatment of diseases
24 May 22
Luke Jonathan Alvey, Denis Maurice Annoot, Florence Marie-Emilie Bonnaterre, Denis Bucher, Béranger Duthion, Hélène Marie Jary, Christophe Peixoto, Taoues Temal-Laib, Amynata Tirera, Nicolas Desroy
Filed: 26 Nov 18
Utility
Pyrazolopyridine Derivatives As Inhibitors of Pask
12 May 22
Stéphane Nicolas Alain BEAUMONT, Xavier Marie BOCK, Daniel COMAS MARTINEZ, Agnès Marie JONCOUR, Frédéric Gilbert LABÉGUÈRE, Miriam LÓPEZ RAMOS, Taoues TEMAL-LAÏB
Filed: 17 Feb 20
Utility
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
11 Jan 22
Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
Filed: 4 May 18
Utility
Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases
2 Dec 21
A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
Christel Jeanne Marie Menet, Koen Kurt Smits
Filed: 14 Apr 21
Utility
Pharmaceutical Compositions Comprising a Jak Inhibitor
18 Nov 21
Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.
David Alonzo, Bei Li, Dimitrios Stefanidis
Filed: 26 Feb 21
Utility
Methods of Administering Therapy
14 Oct 21
The present invention relates to improved methods of administering compound 1 therapy, involving increased effectiveness of compound 1 by avoiding or contraindicating combined CYP3A4/P-gp inducers, e.g. rifampicin.
Julie DESRIVOT, Florence Sylvie NAMOUR
Filed: 7 Aug 19
Utility
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Fibrosis
14 Oct 21
Oscar MAMMOLITI, Koen Karel JANSEN, Christel Jeanne Marie MENET, Adeline Marie Elise PALISSE, Giovanni Alessandro TRICARICO, Sandy EL BKASSINY, Alexis Patrick Claude JAUNET, Brigitte ALLART, Franck Laurent BREBION, Béranger DUTHION
Filed: 21 Jun 18
Utility
5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE Derivatives As Adamts Inhibitors for the Treatment of Osteoarthritis
7 Oct 21
Franck Laurent BREBION, Luke Jonathan ALVEY, David AMANTINI, Frédéric André DE CEUNINCK, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
Filed: 5 Jan 21
Utility
Pyrrolopyrimidine and pyrrolopyridine derivatives
5 Oct 21
David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
Filed: 12 Jul 18
Utility
Methods for the Treatment of Psoriatic Arthritis
30 Sep 21
Pille HARRISON, Luc MEULENERS, Chantal Thérèse TASSET
Filed: 23 May 19
Utility
Novel Salts and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders
2 Sep 21
Nicolas Luc SABOURAULT, Carla DE FAVERI, Ahmad SHEIKH, Piet WIGERINCK
Filed: 8 Jan 21
Utility
High Concentration Liquid Antibody Formulations
19 Aug 21
The present disclosure describes high concentration liquid formulations of a pharmaceutically active antigen binding protein, for example a monoclonal antibody.
Martin DOMNOWSKI, Roy EYLENSTEIN, Jan JAEHRLING, Daniel WEINFURTNER
Filed: 2 Jul 19
Utility
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use
5 Aug 21
Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
Filed: 15 Apr 21
Utility
Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
27 Jul 21
Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
Filed: 13 Nov 19
Utility
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Inflammatory Disorders
10 Jun 21
Steven Emiel VAN DER PLAS, Oscar MAMMOLITI, Sébastien Laurent Xavier MARTINA, Pieter Isabelle Roger CLAES, Ghjuvanni Petru Diunisu COTI, Denis Maurice ANNOOT, Miriam LÓPEZ RAMOS, René Alexandre GALIEN, David AMANTINI, Reginald Christophe Xavier BRYS
Filed: 11 Oct 18
Utility
Compound useful for the treatment of degenerative and inflammatory diseases
11 May 21
Christel Jeanne Marie Menet, Koen Kurt Smits
Filed: 9 May 19
Utility
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
27 Apr 21
Robert J. Altenbach, Andrew Bogdan, Sylvain Couty, Nicolas Desroy, Gregory A. Gfesser, Christopher Gaëtan Housseman, Philip R. Kym, Bo Liu, Thi Thu Trang Mai, Karine Fabienne Malagu, Nuria Merayo Merayo, Olivier Laurent Picolet, Mathieu Rafaël Pizzonero, Xenia B. Searle, Steven Emiel Van der Plas, Xueqing Wang, Ming C. Yeung
Filed: 12 Sep 18
Utility
Novel Compounds and Pharmaceutical Compositions Thereof for the Treatment of Diseases
8 Apr 21
Luke Jonathan ALVEY, Denis Maurice ANNOOT, Florence Marie-Emilie BONNATERRE, Denis BUCHER, Béranger DUTHION, Hélène Marie JARY, Christophe PEIXOTO, Taoues TEMAL-LAIB, Amynata TIRERA, Nicolas DESROY
Filed: 26 Nov 18
Utility
5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
9 Mar 21
Franck Laurent Brebion, Luke Jonathan Alvey, David Amantini, Frédéric André De Ceuninck, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
Filed: 15 Oct 19